Reports & Accounts

Interim Results for the Six Months Ended 31 March 2017 17 May 2017
Annual Report & Accounts 2015-16 29 Mar 2017
Interim Results for the Six Months Ended 31 March 2016 24 May 2016
Annual Report & Accounts 2014-15 21 Jan 2016
Interim Results for the Six Months Ended 31 March 2015 22 Jun 2015

Investor Resources

Presentation - Interim results for the Six Months Ended 31 March 2017 17 May 2017
Hardman & Co research note - Gram-negative antibiotics grant 3 April 2017
Conference Call - Final results for the year ended 30 September 2016 21 Mar 2017
Presentation - Final results for the year ended 30 September 2016 21 Mar 2017
Application Form for Open Share Offer 10 Feb 2017
Proxy for use at General Meeting on 28 February 2017 10 Feb 2017
Circular to Shareholders 10 Feb 2017
Hardman & Co research note - RXC005 BTK inhibitor – watch this space 12 Dec 2016
Hardman & Co research note - Advancing to clinic, increasing value 08 Aug 2016
Proactive Investors speaks to Cantor Fitzgerald about its latest valuation of Redx Pharma, which the analyst says is well on the way to attracting a commercial partner. 13 Jul 2016
AGM Presentation for the year to 30 September 2015 24 Feb 2016
Hardman & Co research note - Pipeline progress — Porcupine Inhibitor 22 Jan 2016
Admission to trading on AIM 27 Mar 2015

Note: Restrictions may apply depending on your country of residence